Crossmark

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Crossref DOI link: https://doi.org/10.1186/s12885-019-5623-3

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jespersen, Henrik

Olofsson Bagge, Roger

Ullenhag, Gustav

Carneiro, Ana

Helgadottir, Hildur

Ljuslinder, Ingrid

Levin, Max

All-Eriksson, Charlotta

Andersson, Bengt

Stierner, Ulrika

Nilsson, Lisa M.

Nilsson, Jonas A.

Ny, Lars http://orcid.org/0000-0003-3864-5958
Funding

Funding for this research was provided by:

Merck (MISP #52933 PEMDAC)

Syndax Pharmaceuticals (SDX-1953)
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 19 November 2018

Accepted: 18 April 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: The study is approved by the regional Ethics Board of Gothenburg, approval number 692–16. Signed and dated informed consent will be obtained from each patient in accordance with the principles of ICH-GCP and the latest version of the Declaration of Helsinki.

: Not applicable.

: ROB, GU, IL, US, ML and LN have had a paid consulting or advisory role with MSD, Sweden. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below